Molecularly targeted therapies in head and neck cancers.

[1]  D. Berney,et al.  The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer , 2013, Clinical Cancer Research.

[2]  M. Nestor,et al.  Targeted therapy in head and neck cancer , 2012, Tumor Biology.

[3]  M. Agulnik.  New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN) , 2012, Medical Oncology.

[4]  J. Grandis,et al.  New advances in molecular approaches to head and neck squamous cell carcinoma , 2011, Anti-cancer drugs.

[5]  G. Piontek,et al.  Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck , 2011, Oncotarget.

[6]  J. Machiels,et al.  Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. , 2011, The Lancet. Oncology.

[7]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[8]  Holger Sudhoff,et al.  Molecular targeted therapies in head and neck cancer - An update of recent developements - , 2010, Head & neck oncology.

[9]  C. Bokemeyer,et al.  Patients and Methods: the European Organisation for Research and Treatment of Cancer Qol Questionnaire , 2022 .

[10]  F. Rivera,et al.  Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial , 2009, Expert review of anticancer therapy.

[11]  R. Kratzke,et al.  Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor , 2009, British Journal of Cancer.

[12]  P. Harari,et al.  Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab , 2009, Cancer biology & therapy.

[13]  J. Dancey,et al.  Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. , 2009, The Lancet. Oncology.

[14]  M. Meyerson,et al.  BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models , 2008, Oncogene.

[15]  Andreas Dietz,et al.  Current aspects of targeted therapy in head and neck tumors , 2008, European Archives of Oto-Rhino-Laryngology.

[16]  G. Pond,et al.  Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Schueler,et al.  Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Armour,et al.  A Phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck , 2007 .

[19]  Jennifer L Hunt,et al.  Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting , 2006, Clinical Cancer Research.

[20]  J. Sterne,et al.  Human papillomavirus and head and neck cancer: a systematic review and meta‐analysis , 2006, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[21]  J. Dancey,et al.  A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Cetuximab Approved by FDA for Treatment of Head and Neck Squamous Cell Cancer , 2006, Cancer biology & therapy.

[23]  M. Goldwasser,et al.  Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Napoleone Ferrara,et al.  VEGF as a Therapeutic Target in Cancer , 2005, Oncology.

[25]  Moshe Talpaz,et al.  Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non–Small Cell Lung Cancer Cells , 2005, Clinical Cancer Research.

[26]  S. Franceschi,et al.  Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review , 2005, Cancer Epidemiology Biomarkers & Prevention.

[27]  J. Siegfried,et al.  Src Family Kinases Mediate Epidermal Growth Factor Receptor Ligand Cleavage, Proliferation, and Invasion of Head and Neck Cancer Cells , 2004, Cancer Research.

[28]  J. Baselga,et al.  Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Antony W Burgess,et al.  Epidermal growth factor receptor: mechanisms of activation and signalling. , 2003, Experimental cell research.

[30]  J. Grandis,et al.  The role of epidermal growth factor receptor in head and neck squamous cell carcinoma , 2003, Current oncology reports.

[31]  A. Godwin,et al.  Expression of constitutively activated EGFRvlll in non‐small cell lung cancer , 2003, Cancer science.

[32]  Ruth Katz,et al.  Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.

[33]  Careen K. Tang,et al.  Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis , 2002, International journal of cancer.

[34]  J. Baselga.  The EGFR as a target for anticancer therapy--focus on cetuximab. , 2001, European journal of cancer.

[35]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[36]  Simon C Watkins,et al.  Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Biegel,et al.  Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. , 1995, Cancer research.

[38]  Jordi Giralt,et al.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.